Showcasts: Page 4

Natera highlights Signatera data at AACR
One study focuses on circulating tumor DNA (ctDNA) prognosis in adjuvant triple-negative breast cancer. Researchers found that 19.9% of patients with early-stage disease were found to have detectable ctDNA after surgery (which was strongly associated with poorer outcomes), and that lead time between first ctDNA positivity and recurrence on imaging was a median of six months.
April 10, 2022
2019 04 15 22 17 2307 Breast Cancer 400
Accounting for genetic factors may improve PSA testing
Presenter Linda Kachuri, PhD, of the University of California, San Francisco, and colleagues investigated whether particular genetic factors could cause variations in PSA levels that are not due to cancer, and whether accounting for these could improve PSA testing. They conducted a study that included 95,000 men with diagnosed prostate cancer from cohorts in the U.S., the U.K., and Sweden and identified 128 PSA-associated variants they used to "build a polygenic score for PSA levels."
April 10, 2022
2019 10 16 20 31 7121 Cancer Cells Prostate 400
AACR 2022: AACR taskforce tackles trust in science
In our video interview, Nodora explains the motivation for establishing a new task force on trust in science, the challenges of community engagement, and how public trust in science has shifted during the COVID-19 pandemic, among other topics.
April 10, 2022
2022 04 11 19 28 3667 Nodora Thumbnail 400
AACR 2022: Video preview of day 3
Even though Sunday is day three of the conference, it is the official launch day of the AACR's annual meeting. LabPulse.com will follow the AACR's presidential address given by AACR President David Tuveson and will talk to Shawn Sweeney, the director of Project GENIE (Genomics Evidence Neoplasia Information Exchange). Watch the video below for more.
April 9, 2022
2022 04 09 20 27 4107 Aacr Sign Square
AACR 2022: What's the microbiome's role in cancer risk?
Tossas, an assistant professor in the department of health behavior and policy at Virginia Commonwealth University, was acknowledged by the AACR as a Next-Gen Star, the organization's program that supports early-career scientists.
April 9, 2022
2022 04 10 15 36 4856 2022 04 10 Tossas Katherine Aacr 400
AACR 2022 video: Pathomics for cancer research
Knudsen addressed the topic of pathomics in cancer research and what that means for the field of pathology.
April 8, 2022
2022 04 10 00 41 7192 2022 04 09 Knudsen 400
Video from AACR 2022: Next-gen pathology tools for cancer research
Knudsen addressed the topic of pathomics in cancer research and what that means for the field of pathology.
April 8, 2022
2022 04 10 00 08 8403 2022 04 09 Knudsen 400
AI spots patients at elevated risk for pancreatic cancer
A team of researchers from the U.S. and Denmark used electronic health record (EHR) data from the Danish National Patient Registry to train their algorithm and then tested it on electronic medical records from Mass General Brigham Health Care System in Boston. Their model proved to be highly accurate for predicting patients at high risk for pancreatic cancer on large datasets from both countries.
April 8, 2022
2020 03 12 20 41 0454 Computer Brain Circuit Ai 400
Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
2020 04 14 22 00 7772 Business Men Handshake 400
C2i Genomics launches MRD test in Europe
The test is the first software-as-a-medical-device MRD test and will be available in countries accepting the CE Mark, according to the company. Recently, it received CE-IVD marking in the European Union, U.K., and Switzerland.
April 5, 2022
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Genialis partners with OncXerna to improve targeted therapy
Genialis' ResponderID will use OncXerna's XernaTME (tumor microenvironment) panel to incorporate the pancancer tumor microenvironment classifier to investigate potentially hundreds of new use cases for personalized therapeutic selection.
April 5, 2022
2019 04 22 23 41 4967 Cancer Cell Target2 400
AACR announces 2022 cancer research award recipients
The award recognizes female researchers who have made pioneering contributions to the understanding and treatment of breast and gynecological cancer. This year's awardees include:
April 3, 2022
2019 09 20 23 44 6333 Trophy Award 400
Previous Page
Page 4 of 6
Next Page